読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$6.31
+$0.36 · +6.05%
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
最新データ
$6.31
+$0.36 · +6.05%
日中の時刻はETです。市場データは遅延する場合があります。
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
81
大幅な割安
センチメント
49
まちまち
リスク
58
やや高いリスク
モメンタム
49
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6185.8万 USD | 5613.4万 USD | 7918.1万 USD | 7366.9万 USD | 6313.4万 USD |
| 売上原価 | 2518.2万 USD | 2087.9万 USD | 2666万 USD | 3077.5万 USD | 3208.4万 USD |
| 粗利益 | 3667.6万 USD | 3525.5万 USD | 5252.1万 USD | 4289.4万 USD | 3105万 USD |
| 研究開発 | 48万 USD | 985.7万 USD | 754.1万 USD | 1094.3万 USD | 1655.8万 USD |
| 販売・一般管理 | 4436.8万 USD | 4020.4万 USD | 4391万 USD | 5946.8万 USD | 3983.3万 USD |
| 営業費用 | 4484.8万 USD | 4893.2万 USD | 5459.4万 USD | 7041.1万 USD | 6593.1万 USD |
| 受取利息 | 58.9万 USD | 75.7万 USD | 32.2万 USD | 6万 USD | 2000 USD |
| 支払利息 | 369.8万 USD | 270万 USD | 169.8万 USD | 201.9万 USD | 703.4万 USD |
| 減価償却費と償却費 | 434.6万 USD | 351.5万 USD | 385.5万 USD | 436.5万 USD | 256万 USD |
| 営業利益 | −817.2万 USD | −1367.7万 USD | −207.3万 USD | −2751.7万 USD | −3488.1万 USD |
| 純利益 | −1143.1万 USD | −1467.2万 USD | −385.3万 USD | −2962.8万 USD | −4399.4万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$11.75
上昇余地（86.21%）評価サンプルは3件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI348.59万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF138.54万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC26.33万0.02%13.17億 USD0.60%$183+0.11%
Invesco NASDAQ Future Gen 200 ETFQQQS9.63万0.43%2244.62万 USD0.20%$42.145+1.39%
U.S. Micro Cap Portfolio ETFDFMC4万0.00%75.58億 USD0.43%$57.813+0.20%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.69万0.00%455.91億 USD0.17%$84.44+0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSU.S. Micro Cap Portfolio ETFDFMCU.S. Core Equity 1 Portfolio ETF Class SharesDCORAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
